S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.21
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.51
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
MLAB · Mesa Laboratories, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Mesa Laboratories Inc (MLAB)
NASDAQ NMS - GLOBAL MARKET
Life Sciences Tools & Services
$129.42
+2.43
(+1.91%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$129.42
$123.76
$129.42
52-WEEK RANGE
$129.42
$69.51
$144.35
What's happening
- MLAB is up 1.91% today, trading at $129.42. — Live quote
- Volume today (3,617) is well below its 3-month average of 161,010. (Finnhub fundamentals)
- Reports earnings on 2026-11-05, 14 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $0.49 actual vs. $0.03 estimated (+1501.3%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 3
Hold 2
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (8 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
MLAB
+59.44%
vs S&P 500
+46.66%
1-YEAR RETURN
MLAB
+63.74%
vs S&P 500
+49.17%
6-MONTH RETURN
MLAB
+26.74%
3-MONTH RETURN
MLAB
+28.36%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q1 2027)
$0.49
Est. $0.03
BEAT +1501.3%
2026-07-26 (Q2 2026)
$0.49
Est. $0.03
BEAT +1501.3%
2026-04-26 (Q1 2026)
$-0.75
Est. $0.35
MISS -316.3%
2025-04-26 (Q4 2025)
$-1.31
Est. $1.11
MISS -217.8%
Valuation Measures & Ratios
Enterprise Value4$827.3M
Forward P/E550.20
PEG Ratio6—
Price / Sales (TTM1)2.86
Price / Book72.91
EV4 / Revenue3.31
EV4 / EBITDA22.04
Profit Margin1.92%
Operating Margin9.00%
Return on Equity (ROE8)2.59%
Return on Assets (ROA9)1.12%
Avg Volume (3M)161,010
Quarterly history (5 periods)
| Measure | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 |
|---|---|---|---|---|---|
| Market cap | $575.1M | $433.8M | $365.9M | $522.3M | $708.9M |
| P/E | 42.04 | 47.29 | 40.79 | 52.85 | 97.71 |
| Price/Sales | 2.34 | 1.75 | 1.52 | 2.19 | 3.05 |
| Price/Book | 3.05 | 2.32 | 2.05 | 3.03 | 4.57 |
| EV/Revenue | 2.49 | 1.91 | 1.72 | 2.40 | 3.24 |
| ROE | 7.25% | 4.91% | 5.03% | 5.73% | 4.67% |
| ROA | 3.26% | 2.11% | 2.08% | 2.27% | 1.67% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short447,048
Change from Prior Settlement+10.78%
% of Float—
Days to Cover (Short Ratio)3.70
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Revenue growth is 1.0% on the provider's reported measure. Finnhub fundamentals ↗
- Trailing 52-week price return is +63.7%. Finnhub market metrics ↗
Potential concerns
- Net profit margin is 1.9%. Finnhub fundamentals ↗
- Trailing P/E is 149.0, a high price relative to reported earnings. Finnhub fundamentals ↗
- Latest SEC filing is Form 8-K, filed 2026-10-13; review it for current changes and risks. SEC EDGAR ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on MLAB
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Dec '25 | Sep '25 | Jun '25 | Dec '24 | Sep '24 | Jun '24 | Dec '23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $60.1M | $65.1M | $60.7M | $59.5M | $62.8M | $57.8M | $58.2M | $53.5M |
| Gross profit | $39.0M | $41.8M | $37.3M | $36.9M | $39.8M | $35.5M | $37.2M | $33.4M |
| Operating income | $7.0M | $8.0M | $4.7M | $3.1M | $5.8M | $3.5M | $5.6M | -$67.0K |
| Net income | $2.8M | $3.6M | $2.5M | $4.7M | -$1.7M | $3.4M | $3.4M | $2.1M |
| EPS (diluted) | $0.49 | $0.65 | $0.45 | $0.85 | $-0.31 | $0.63 | $0.62 | $0.39 |
| EPS (basic) | $0.50 | $0.66 | $0.45 | $0.87 | $-0.31 | $0.63 | $0.63 | $0.39 |
| Operating margin | $12 | $12 | $8 | $5 | $9 | $6 | $10 | -$0 |
| Net margin | $5 | $6 | $4 | $8 | -$3 | $6 | $6 | $4 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $419.2M | $427.7M | $434.8M | $430.4M | $435.7M | $433.3M | $433.3M | $454.1M |
| Total liabilities | $230.5M | $241.5M | $248.2M | $251.9M | $263.2M | $273.5M | $273.5M | $292.6M |
| Stockholders' equity | $188.8M | $186.2M | $186.7M | $178.5M | $172.5M | $159.8M | $155.2M | $161.5M |
| Total current assets | $102.8M | $106.3M | $105.6M | $97.4M | $98.3M | $102.7M | $102.7M | $108.0M |
| Total current liabilities | $57.3M | $61.9M | $54.4M | $48.3M | $149.5M | $164.0M | $164.0M | $153.2M |
| Cash & equivalents | $30.7M | $26.9M | $29.0M | $20.4M | $21.3M | $27.3M | $27.3M | $24.3M |
| Accounts receivable | $34.4M | $44.1M | $40.2M | $40.1M | $39.1M | $42.0M | $42.0M | $40.2M |
| Inventory | $27.2M | $26.4M | $26.6M | $27.7M | $28.1M | $25.4M | $25.4M | $29.7M |
| Other current assets | $4.5M | $3.6M | $3.9M | $3.6M | $3.3M | $2.9M | $2.8M | $3.9M |
| Property, plant & equipment | $30.1M | $30.6M | $31.6M | $31.8M | $31.7M | $32.3M | $32.3M | $32.1M |
| Goodwill | $186.0M | $186.9M | $189.3M | $188.5M | $188.1M | $181.8M | $181.8M | $183.8M |
| Intangible assets | $78.4M | $83.3M | $89.6M | $93.3M | $97.4M | $96.9M | $98.2M | $108.8M |
| Other non-current assets | $20.4M | $19.2M | $17.2M | $17.9M | $18.9M | $18.3M | $18.3M | $20.1M |
| Accounts payable | $7.5M | $4.9M | $5.3M | $5.1M | $6.3M | $5.7M | $5.7M | $6.0M |
| Accrued liabilities | $16.5M | $17.6M | $15.5M | $14.2M | $16.1M | $24.6M | $24.6M | $22.9M |
| Deferred revenue (current) | $14.5M | $14.7M | $14.6M | $14.3M | $15.1M | $14.7M | $14.7M | $14.4M |
| Short-term debt | — | — | — | — | — | — | — | — |
| Long-term debt | $66.1M | $67.5M | $68.4M | $69.4M | $70.3M | $71.2M | $72.2M | $73.1M |
| Other non-current liabilities | — | $13.7M | $11.0M | $11.8M | $12.7M | $12.5M | $12.5M | $14.7M |
| Common stock & paid-in capital | $376.7M | $375.3M | $368.6M | $365.2M | $361.4M | $358.5M | $358.5M | $349.5M |
| Retained earnings | -$183.8M | -$185.7M | -$180.7M | -$183.5M | -$185.1M | -$188.9M | -$188.9M | -$178.4M |
| Accumulated other comprehensive income (loss) | -$4.2M | -$3.4M | -$1.1M | -$3.2M | -$3.8M | -$9.8M | -$9.8M | -$9.7M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.7M | $14.0M | $18.8M | $8.2M | $1.9M | $12.7M | $18.1M | $5.3M |
| Investing cash flow | -$559.0K | -$417.0K | -$732.0K | -$1.1M | -$1.0M | -$1.0M | -$813.0K | -$1.8M |
| Financing cash flow | -$10.5M | -$15.8M | -$9.8M | -$7.9M | -$8.4M | -$16.2M | -$10.3M | -$8.6M |
| Free cash flow | $14.2M | $13.5M | $18.0M | $7.1M | $884.0K | $11.9M | $17.3M | $3.5M |
| Capital expenditures | $559.0K | $417.0K | $732.0K | $1.1M | $1.0M | $757.0K | $813.0K | $1.8M |
| Depreciation & amortization | — | — | — | — | — | — | — | — |
| Share-based compensation | $2.4M | $6.8M | $3.4M | $3.8M | $3.9M | $3.1M | $3.2M | $3.8M |
| Deferred income taxes | — | -$1.3M | — | — | — | -$61.0K | — | — |
| Change in accounts receivable | -$9.8M | $4.1M | $819.0K | $1.7M | -$3.4M | $3.0M | -$657.0K | $4.0M |
| Change in inventory | $1.5M | $974.0K | -$596.0K | $766.0K | $3.3M | -$1.7M | $495.0K | -$627.0K |
| Change in accounts payable | $2.4M | -$324.0K | $124.0K | -$1.2M | $212.0K | $1.5M | -$1.7M | $199.0K |
| Dividends paid | $884.0K | $884.0K | $884.0K | $882.0K | $873.0K | $870.0K | $869.0K | $866.0K |
| Share repurchases | — | — | — | — | — | — | — | — |
| Tax withholding on stock comp | $958.0K | $0 | — | — | $1.1M | $887.0K | — | — |
| Other financing activities | — | $873.0K | -$214.0K | -$564.0K | -$1.1M | $858.0K | $20.0K | -$307.0K |
Income statement
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Revenue | $249.1M | $241.0M | $216.2M | $219.1M | $184.3M |
| Gross profit | $158.3M | $150.9M | $133.2M | $133.7M | $109.1M |
| Operating income | $18.5M | $16.3M | -$272.1M | $3.3M | $4.7M |
| Net income | $6.7M | -$2.0M | -$254.2M | $930.0K | $1.9M |
| EPS (diluted) | $1.21 | $-0.36 | $-47.20 | $0.17 | $0.35 |
| EPS (basic) | $1.22 | $-0.36 | $-47.20 | $0.17 | $0.36 |
| Operating margin | $7 | $7 | -$126 | $2 | $3 |
| Net margin | $3 | -$1 | -$118 | $0 | $1 |
Balance sheet
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Total assets | $427.7M | $433.3M | $446.8M | $661.8M | $707.4M |
| Total liabilities | $241.5M | $273.5M | $301.4M | $268.4M | $313.6M |
| Stockholders' equity | $186.2M | $159.8M | $145.4M | $393.5M | $393.8M |
| Total current assets | $106.3M | $102.7M | $109.4M | $119.0M | $124.3M |
| Total current liabilities | $61.9M | $164.0M | $44.3M | $43.4M | $48.1M |
| Cash & equivalents | $26.9M | $27.3M | $28.2M | $32.9M | $49.3M |
| Accounts receivable | $44.1M | $42.0M | $39.1M | $42.6M | $41.2M |
| Inventory | $26.4M | $25.4M | $32.7M | $34.6M | $24.6M |
| Other current assets | $3.6M | $2.9M | $3.3M | $4.0M | — |
| Property, plant & equipment | $30.6M | $32.3M | $31.8M | $28.1M | $28.6M |
| Goodwill | $186.9M | $181.8M | $180.1M | $286.4M | $291.2M |
| Intangible assets | $83.3M | $96.9M | $113.8M | $216.8M | $250.1M |
| Other non-current assets | $19.2M | $18.3M | $10.5M | $10.4M | $11.8M |
| Accounts payable | $4.9M | $5.7M | $6.0M | $6.1M | $7.9M |
| Accrued liabilities | $17.6M | $24.6M | $12.9M | $12.1M | $11.6M |
| Deferred revenue (current) | $14.7M | $14.7M | $15.5M | $15.7M | $13.8M |
| Short-term debt | — | — | — | — | — |
| Long-term debt | $67.5M | $71.2M | — | — | — |
| Other non-current liabilities | $13.7M | $12.5M | $15.6M | $6.2M | $7.9M |
| Common stock & paid-in capital | $375.3M | $358.5M | $343.6M | $332.1M | $313.5M |
| Retained earnings | -$185.7M | -$188.9M | -$183.5M | $74.2M | $76.7M |
| Accumulated other comprehensive income (loss) | -$3.4M | -$9.8M | -$14.8M | -$12.8M | $3.7M |
Cash flow
| Line item | Mar '26 | Mar '25 | Mar '24 | Mar '23 | Mar '22 |
|---|---|---|---|---|---|
| Operating cash flow | $42.8M | $46.8M | $44.1M | $28.0M | $39.2M |
| Investing cash flow | -$3.2M | -$4.5M | -$81.3M | -$9.5M | -$305.2M |
| Financing cash flow | -$41.9M | -$44.5M | $32.8M | -$33.3M | $52.6M |
| Free cash flow | $39.6M | $42.6M | $41.6M | $23.4M | $34.8M |
| Capital expenditures | $3.2M | $4.2M | $2.6M | $4.5M | $4.4M |
| Depreciation & amortization | — | — | — | $33.8M | $25.1M |
| Share-based compensation | $17.9M | $13.1M | $11.9M | $12.5M | $11.4M |
| Deferred income taxes | -$1.3M | -$61.0K | -$28.4M | -$3.5M | $128.0K |
| Change in accounts receivable | $3.2M | $2.9M | -$4.9M | $2.1M | $6.8M |
| Change in inventory | $4.4M | -$1.2M | -$2.6M | $10.2M | $1.0M |
| Change in accounts payable | -$1.2M | -$388.0K | -$97.0K | -$1.5M | $1.4M |
| Dividends paid | $3.5M | $3.5M | $3.4M | $3.4M | $3.3M |
| Share repurchases | — | — | — | — | — |
| Tax withholding on stock comp | $1.1M | $887.0K | $728.0K | $919.0K | $875.0K |
| Other financing activities | -$966.0K | -$452.0K | -$847.0K | $0 | -$237.0K |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding MLAB as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-06-15 to 2026-08-15
Recent transactions
- Insiders have net sold 7,377 shares over the last 182 days, across 2 purchases and 7 sales.
- Most recent: Capone Mark Christopher (Director) — Option exercise of 2,784 shares on 2026-08-15.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)7,993 sh(2 txns)
Sales (open market)15,370 sh(7 txns)
Net Shares-7,377
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Capone Mark Christopher | Director | Option exercise | 2026-08-15 | 2,784 |
| Alltoft Jennifer Sadie | Director | Option exercise | 2026-08-15 | 2,784 |
| Ladiwala Shiraz Shabanali | Director | Option exercise | 2026-08-15 | 3,810 |
| Hall Shannon | Director | Option exercise | 2026-08-15 | 2,784 |
| Tripeny R Tony | Director | Option exercise | 2026-08-15 | 2,784 |
| Sullivan John James | Director | Option exercise | 2026-08-15 | 2,784 |
| Kadia Siddhartha | President and CEO | Open market purchase | 2026-08-13 | 7,093 |
| Crennen Lyndsey Elizabeth | CAO | Open market sale | 2026-06-22 | 442 |
| Archbold Brian David | SVP Operations | Open market sale | 2026-06-22 | 2,516 |
| Sakys John | CFO | Open market sale | 2026-06-22 | 2,827 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-15 | Capone Mark Christopher | Director | Option exercise | 2,784 | $0.00 |
| 2026-08-15 | Alltoft Jennifer Sadie | Director | Option exercise | 2,784 | $0.00 |
| 2026-08-15 | Ladiwala Shiraz Shabanali | Director | Option exercise | 3,810 | $0.00 |
| 2026-08-15 | Hall Shannon | Director | Option exercise | 2,784 | $0.00 |
| 2026-08-15 | Tripeny R Tony | Director | Option exercise | 2,784 | $0.00 |
| 2026-08-15 | Sullivan John James | Director | Option exercise | 2,784 | $0.00 |
| 2026-08-13 | Sullivan John James | Director | Open market sale | 7,093 | $112.80 |
| 2026-08-13 | Kadia Siddhartha | President and CEO | Open market purchase | 7,093 | $112.80 |
| 2026-08-13 | Tripeny R Tony | Director | Open market purchase | 900 | $113.69 |
| 2026-06-22 | Crennen Lyndsey Elizabeth | CAO | Open market sale | 442 | $89.50 |
| 2026-06-22 | Archbold Brian David | SVP Operations | Open market sale | 2,516 | $89.50 |
| 2026-06-22 | Sakys John | CFO | Open market sale | 2,827 | $89.50 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | CAO | Option exercise | 125 | $95.10 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | CAO | Option exercise | 233 | $95.10 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | CAO | Option exercise | 368 | $95.10 |
| 2026-06-18 | Crennen Lyndsey Elizabeth | CAO | Grant / award | 263 | $95.10 |
| 2026-06-18 | Archbold Brian David | SVP Operations | Option exercise | 844 | $95.10 |
| 2026-06-18 | Archbold Brian David | SVP Operations | Option exercise | 2,480 | $95.10 |
| 2026-06-18 | Archbold Brian David | SVP Operations | Grant / award | 1,859 | $95.10 |
| 2026-06-18 | Sakys John | CFO | Option exercise | 1,036 | $95.10 |
| 2026-06-18 | Sakys John | CFO | Option exercise | 2,756 | $95.10 |
| 2026-06-18 | Sakys John | CFO | Grant / award | 2,282 | $95.10 |
| 2026-06-16 | Archbold Brian David | SVP Operations | Open market sale | 1,151 | $101.27 |
| 2026-06-16 | Crennen Lyndsey Elizabeth | CAO | Open market sale | 118 | $101.27 |
| 2026-06-16 | Sakys John | CFO | Open market sale | 1,223 | $101.27 |
| 2026-06-15 | Archbold Brian David | SVP Operations | Option exercise | 2,454 | $104.08 |
| 2026-06-15 | Sakys John | CFO | Option exercise | 2,717 | $104.08 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 02:09 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-13 | 8-K | 2026-10-12 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-11 | 4 | 2026-09-09 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-15 | View on SEC.gov → |
| 2026-08-17 | 4 | 2026-08-15 | View on SEC.gov → |
Recent news
Headlines about MLAB (Mesa Laboratories, Inc.). Links open the publisher — we don’t host full articles.
-
Mesa Laboratories keeps USD 0.16 dividend for Mesa Laboratories stock
AD HOC NEWS · 2026-10-20 -
Mesa Laboratories stock fell 4.12 percent to USD 122.48 on October 16, 2026
AD HOC NEWS · 2026-10-17 -
Mesa Laboratories, Inc. Stock Price Today | MLAB Live Chart & News
Traders Union · 2026-10-17 -
Mesa Laboratories, Inc. (MLAB) Stock Price, News, Quote & History
Yahoo! Finance Canada · 2026-10-16 -
Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data
RTTNews · 2026-10-16 -
WASATCH ADVISORS LP Boosts Mesa Laboratories Inc (MLAB) Stake -- Shares Look 19% Overvalued on GF Value
GuruFocus · 2026-10-15 -
Mesa Laboratories announces $9.3M cost-savings plan
Seeking Alpha · 2026-10-13 -
Mesa Laboratories Announces Restructuring and Savings Plan to Reduce Annualized Costs by Approximately $9.3 Million and Reinvest Approximately $4.3 Million in Profitable Growth
Yahoo · 2026-10-13
No headlines in this category right now — try “All”.